Antiplatelets In The Wilderness After Mixed Results From DAPT Study
FDA seems more concerned about mortality than most academics following trial of dual antiplatelet therapy after stenting; AstraZeneca sees potential opening for Brilinta.
FDA seems more concerned about mortality than most academics following trial of dual antiplatelet therapy after stenting; AstraZeneca sees potential opening for Brilinta.